ERAS Erasca, Inc.
Price Chart
Executive Summary
Erasca announced a clinical trial collaboration with Merck to evaluate its pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA for RAS-mutant solid tumors. Merck will supply pembrolizumab at no cost, and Erasca will sponsor the AURORAS-1 study. This is a non-financial collaboration that provides validation for Erasca's pipeline but does not change the company's fundamental outlook.
Actionable Insight
This collaboration provides clinical validation and cost savings but does not alter Erasca's near-term cash burn or regulatory path. Monitor AURORAS-1 enrollment and early efficacy data for read-through on ERAS-0015's potential. The stock may see a modest positive reaction on partnership credibility, but no fundamental change.
Key Facts
- Erasca entered a clinical trial collaboration and supply agreement with Merck for ERAS-0015 + KEYTRUDA in RAS-mutant solid tumors.
- Merck is supplying pembrolizumab at no cost; Erasca sponsors the AURORAS-1 study.
- ERAS-0015 is an oral pan-RAS molecular glue with early Phase 1 data showing favorable safety and partial responses at doses as low as 8 mg QD.
- Approximately 2.7 million patients are diagnosed annually with RAS-mutant tumors worldwide.
- No financial terms of the agreement were disclosed.
Financial Impact
No financial terms disclosed; Merck's supply of pembrolizumab at no cost reduces Erasca's trial expenses modestly.
Risk Factors
- ERAS-0015 is still in early Phase 1; clinical failure remains a significant risk.
- Revolution Medicines has alleged patent infringement regarding ERAS-0015, which could lead to litigation delays.
- Combination trial may not show additive benefit over monotherapy or existing standards.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Institutional Cluster
| $14.03 awaiting T+5 | awaiting T+5 | — | $14.05 (+0.18%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $13.70 awaiting T+5 | awaiting T+5 | — | $14.05 (+2.55%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $13.13 awaiting T+5 | awaiting T+5 | — | $14.05 (+7.01%) |
|
May 11, 2026
4w ago
|
Press Release
| $10.44 $10.27 | ▼ −1.63% | ▼ −1.54% | $14.05 (+34.58%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $9.11 $9.99 | ▲ +9.66% | ▲ +6.55% | $14.05 (+54.23%) |
|
Apr 27, 2026
6w ago
|
8-K
| $9.90 $10.14 | ▲ +2.42% | ▲ +0.73% | $14.05 (+41.92%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $9.90 $10.14 | ▲ +2.42% | ▲ +0.73% | $14.05 (+41.92%) |
|
Apr 27, 2026
6w ago
|
8-K
| $19.15 $10.14 | ▼ −47.05% | ▼ −47.45% | $14.05 (−26.63%) |
|
Apr 21, 2026
7w ago
|
8-K
| $22.41 $9.90 | ▼ −55.82% | ▼ −56.91% | $14.05 (−37.30%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $13.62 $14.60 | ▲ +7.20% | ▲ +9.31% | $14.05 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access